A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
Status:
Completed
Trial end date:
2020-06-05
Target enrollment:
Participant gender:
Summary
Phase 2a multicenter, open-label, parallel-arm design study to evaluate the safety,
tolerability and pharmacodynamics of a single intravitreal injection comparing 2 dose levels
of GB-102 on subjects with Diabetic Macular Edema and Retinal Vein Occlusion